MENA Market: An Attractive Opportunity for Rare Disease and Healthcare Companies
March 4, 2013
The MENA region is very diverse, but one thing the countries in this region have in common is that their economies show sustainable “emerging market-type growth.”
This growth and contributing socio-economic factors have had a significant impact on the healthcare sector, with governments “investing in healthcare infrastructures, in access to medicine and reimbursement schemes. Moreover, there is a clear trend towards privatizing medical insurance.”
The whitepaper goes on to look at several key topics, including:
■ MENA Socio-Economic characteristics
■ Healthcare Spending and Investment
■ Pharma Market Trends
■ Pharma Brands and Generics
■ Genetic Diseases in the Middle East
■ Intellectual Property Protection Legislation
■ Pharmaceutical Regulatory and Pricing
■ Orphan Drug Business Models and Market Access
Get your copy of the whitepaper HERE.
With an estimated 2.8 million patients suffering from a rare disease in the Middle East region, this truly is an interesting and unique frontier in the rare disease and orphan drug space. And, perhaps more importantly, the rare disease community in the MENA region really need—and deserve—easy access to treatments for their diseases.
GENPHARM is an associate sponsor of the upcoming World Orphan Drug Congress USA.
Caroline Hornby, Marketing Director for Terrapinn’s Americas business, is currently working on World Orphan Drug Congress USA. She is excited to be bringing together an audience of patient groups, government, academia and industry to further orphan drug discovery.
Sign up for updates straight to your inbox.